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OBJECTIVES: The clinical significance of ischemia/reperfusion of the lower extremities demands further
investigation to enable the development of more effective therapeutic alternatives. This study investigated the
changes in the vascular reactivity of the rabbit femoral artery and nitric oxide metabolites under partial ischemia/
reperfusion conditions following cilostazol administration.
METHODS: Ischemia was induced using infrarenal aortic clamping. The animals were randomly divided into seven
groups: Control 90 minutes, Ischemia/Reperfusion 90/60 minutes, Control 120 minutes, Ischemia/Reperfusion 120/90
minutes, Cilostazol, Cilostazol before Ischemia/Reperfusion 120/90 minutes, and Ischemia 120 minutes/Cilostazol/
Reperfusion 90 minutes. Dose-response curves for sodium nitroprusside, acetylcholine, and the calcium ionophore
A23187 were obtained in isolated femoral arteries. The levels of nitrites and nitrates in the plasma and skeletal
muscle were determined using chemiluminescence.
RESULTS: Acetylcholine- and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group,
and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment. Only
cilostazol treatment increased plasma levels of nitrites and nitrates. An elevation in the levels of nitrites and nitrates
was observed in muscle tissues in the Ischemia/Reperfusion 120/90, Cilostazol/Ischemia/Reperfusion, and Ischemia/
Cilostazol/Reperfusion groups.
CONCLUSION: Hind limb ischemia/reperfusion yielded an impaired endothelium-dependent relaxation of the
femoral artery. Furthermore, cilostazol administration prior to ischemia exerted a protective effect on endothelium-
dependent vascular reactivity under ischemia/reperfusion conditions.
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INTRODUCTION
The mechanisms of arterial occlusion are clearly asso-
ciated with endothelial function, and these mechanisms are
strongly affected by ischemia and blood reperfusion.
Endothelial dysfunction is caused by impaired nitric oxide
(NO) release or a decrease in NO bioavailability, which
increases the risk of blood vessel spasm and thrombosis.
Cilostazol exerts a protective effect on various vascular
tissues following acute ischemia (1-3), and it alleviates
the symptoms of intermittent claudication in peripheral
vascular disease patients. This compound is a selective in-
hibitor of phosphodiesterase 3 (PDE3), which raises intracel-
lular cyclic adenosine monophosphate (cAMP) content and
activates protein kinase A (PKA). These events culminate in
antiplatelet aggregation and peripheral vasodilation (4).
The role of the NO pathway on the pharmacological
action of cilostazol remains largely unknown. Therefore,
this study investigated the effects on NO/endothelium-
dependent femoral reactivity in vitro, as induced by an in
vivo cilostazol infusion. Rabbit hind limb global ischemia
was induced using infrarenal abdominal aortic cross-
clamping followed by reperfusion. The femoral artery wall
response was examined because of its importance in the
propagation of arterial blood throughout the hind limb.
METHODS
Drugs. Acetylcholine chloride (ACh), the calcium iono-
phore (A23187), sodium nitroprusside (SNP), phenylephrine
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(Phe), indomethacin, and cilostazol (Cil) were purchased
from Sigma Chemical Company (St. Louis, MO, USA).
SNP, ACh, and Phe were dissolved in distilled water.
Indomethacin was dissolved in ethanol (10-5 M), and the
calcium ionophore was first dissolved in dimethylsulfoxide
(DMSO) and was subsequently diluted in water. Cilostazol
was first dissolved in DMSO (10 mg/ml), and the 1 mg/kg
dose was prepared by the dilution of this solution with saline
to a volume of 5 ml. This dose was intravenously
administered for 20 minutes (5).
Experimental design. Male rabbits (2 2.5 kg) were pre-
anesthetized with ketamine hydrochloride (KetalarH, 5 mg/
kg IM) and xylazine hydrochloride (RompunH, 10 mg/kg
IM), and they were anesthetized using pentobarbital sodium
(30 mg/kg IV). The animals underwent tracheostomy, and
they were ventilated using an endotracheal tube (3.0 mm,
Rusch, Teleflex Medical, Durham, NC, USA) with 100% O2
in a pressure-controlled mode (Takaoka 600, K. Takaoka
Indu´stria e Come´rcio Ltda, Sa˜o Bernardo do Campo, SP,
Brazil). The ear marginal artery was cannulated for volemic
reposition with saline solution (NaCl 0.9%, 10 ml/kg/h).
The abdominal infrarenal aorta was exposed using a median
transperitoneal laparotomy approach, and a vascular clamp
was applied to produce ischemia. The Institutional Animal
Care and Use Committee of the School of Medicine of
Ribeira˜o Preto, University of Sa˜o Paulo, Brazil reviewed and
approved the procedures for animal handling, which were
in accordance with the Guide for the Care and Use of
Laboratory Animals published by the U.S. National
Institutes of Health (NIH Publication No. 85-23, revised
1996).
The animals were randomly divided into two main
experimental groups, specifically, those treated without
cilostazol (Group I - 4 subgroups) and with cilostazol
(Group II - 3 subgroups): 1) Control 90 (anesthesia for 150
minutes); 2) Control 120 (anesthesia for 210 minutes); 3) I/R
90/60 (90 minutes of ischemia followed by 60 minutes of
reperfusion); 4) I/R 120/90 (120 minutes of ischemia
followed by 90 minutes of reperfusion); 5) Cil (endovenous
cilostazol administered after anesthesia); 6) Cil/I/R (endo-
venous cilostazol administered before ischemia and sub-
mission of rabbits to 120 minutes of ischemia followed by 90
minutes of reperfusion); and 7) I/Cil/R (120 minutes of
ischemia followed by cilostazol administration and reperfu-
sion). Subgroups 1 and 2 from Group I were sham operation
groups with different anesthesia times (120 and 210
minutes, respectively). Subgroups 3 and 4 from Group I
(without cilostazol) underwent different durations of
ischemia (90 and 120 minutes, respectively). Subgroups
5, 6, and 7 from Group II (with cilostazol) were used to
investigate the isolated action of cilostazol and its protective
effect when infused prior to or after 120 minutes of ischemia
followed by 90 minutes of reperfusion (Figure 1).
Vascular reactivity. The femoral artery was carefully
exposed through an anterior-medial hind limb incision and
was immersed in Krebs solution composed of the following
(in mM): NaCl 118.3, KCl 4.7, MgSO4 1.66, KH2PO4 1.22,
CaCl2 2.5, NaHCO3 25.0, and glucose 11.1. Femoral artery
segments (4-5 mm in length) were prepared with caution to
avoid damage to the intimal surface of the vascular
segments. The endothelium was removed by the gentle
rubbing of the intimal surface of the blood vessel with a pair
of watchmaker’s forceps to investigate vascular smooth
muscle function without the influence of the endothelium.
This procedure removes the endothelium, but it does not
affect vascular smooth muscle contraction. Vascular
segments with and without endothelium were suspended
in organ chambers (10 ml) filled with Krebs solution,
maintained at 37 C˚ and bubbled with 95% O2/5% CO2
(pH = 7.4). Each ring was suspended using two stainless
Figure 1 - Diagram of study design illustrating the following subgroups within Group I (without cilostazol) and Group II (with
cilostazol): 1) Control 90 (anesthesia for 150 minutes); 2) Control 120 (anesthesia for 210 minutes); 3) I/R 90/60 (90 minutes of ischemia
followed by 60 minutes of reperfusion); 4) I/R 120/90 (120 minutes of ischemia followed by 90 minutes of reperfusion); 5) Cil
(endovenous cilostazol administered after anesthesia); 6) Cil/I/R (endovenous cilostazol administered before ischemia and submission of
rabbits to 120 minutes of ischemia followed by 90 minutes of reperfusion); and 7) I/Cil/R (120 minutes of ischemia followed by cilostazol
administration and reperfusion).
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steel clips that passed through the lumen. One clip was
anchored to the bottom of the organ chamber, and the other
clip was connected to a strain gauge for the measurement of
isometric force (Grass FT03; Grass Instrument Company,
Quincy, MA). Each ring was stretched to the optimal length-
tension of 2 g (determined in a pilot study) and equilibrated
for 60 minutes. Tissues were washed every 20 minutes
during the equilibration period. Endothelial integrity was
assessed by the degree of ACh-induced (10-6 M) relaxation
in rings that were precontracted with Phe (10-6 M). The
endothelium was present when the ACh-induced relaxation
was 80% or greater. Each ring was washed and re-
equilibrated for 30 minutes in the presence of
indomethacin (10-5 M) to exclude the cyclooxygenase
effects from the analysis because the NO pathway was the
target of the investigation. The femoral artery rings were
preincubated with Phe (10-6 M), and dose-response curves
for SNP, ACh, and A23187 were obtained after the rings
reached a stable plateau.
Nitrite and nitrate (NOx) quantification. Blood samples
from the cava vein were collected in tubes containing
heparin (1520 v/v). The blood was centrifuged (30006g, 10
minutes, 4 C˚), and plasma aliquots were stored at -70 C˚ for
subsequent NOx measurement. Muscle (gracilis) tissue
samples were wrapped and immediately stored at -70 C˚.
The muscle samples were homogenized in Tris-HCl
(20 mM, pH 7.4, 10% w/v) for analysis. The homogenate
was centrifuged (30006g, 10 minutes, 4 C˚), and the
supernatant was used to measure NOx concentrations and
total protein using the modified biuret reaction (6). Plasma
and muscle samples were analyzed using an ozone-based
chemiluminescence assay. Briefly, the samples were treated
Figure 2 - Femoral artery concentration-response curves. (A, D) ACh (10-10 to 3.10-5 M); (B, E) A23187 (10-10 to 3.10-5 M); and (C, F) SNP
(10-10 to 3.10-5 M) from the Control and I/R groups. * Indicates the difference between the Control 120 and I/R 120/90 groups (p,0.05).
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with cold ethanol (152 v/v for 30 minutes at -20 C˚) and
centrifuged (40006g, 10 min). NOx levels were measured by
injecting 25 mL of the supernatant into a glass purge vessel
containing 0.8% vanadium (III) in HCl (1 N) at 90 C˚, which
reduces NOx to an NO gas. A nitrogen stream was bubbled
through the purge vessel, which contained vanadium (III),
and through NaOH (1 N) into an NO analyzer (SieversH
Nitric Oxide Analyzer 280, GE Analytical Instruments,
Boulder, CO, USA). The NOx concentration was calculated
from a standard curve (sodium nitrate 0.5, 1.5, 10, and
50 mM), and it is expressed in mM for plasma and mM/mg
protein for muscle samples.
Statistical analysis. The results are expressed as means
¡ the standard error of the mean (SEM). The dose-response
curves for ACh, A23187, and SNP were derived using
molar concentrations, and the logarithm of the molar
concentration (log [M]) is presented in the three figures of
figure 3. The EC50 was calculated from the dose-response
curves of SNP), ACh, and A23187. The concentration-
response curves were analyzed using two-way repeated-
measures analysis of variance (ANOVA) and Bonferroni
post-hoc tests. The concentrations of NOx were assessed
using a one-way ANOVA (Prism 4.0, GraphPad Software,
Inc., San Diego, CA, USA). Values were considered to be
statistically significant at p,0.05.
RESULTS
Vascular reactivity. ACh and A23187 promoted
concentration-dependent relaxation in femoral artery
endothelium-intact rings, and this relaxation was reduced
in the I/R 120/90 group (Figures 2A and 2B). SNP produced
a concentration-dependent relaxation in femoral artery
endothelium-denuded rings, and no intergroup statistical
differences were observed (Figure 2C). Cilostazol treatment
impaired ACh- and A23187-induced relaxation (Figures 3A
and 3B), but cilostazol did not alter SNP-induced relaxation
(Figure 3C). Cilostazol administration prior to the induction
of ischemia partially prevented the ischemia/reperfusion-
induced impairment of ACh- and A23187-induced
relaxation (Figures 4A and 4B). No change in SNP-
induced relaxation was observed (Figure 4C). The EC50
values of sodium nitroprusside (SNP), acetylcholine (ACh),
and the calcium ionophore (A23) are listed in Table 1.
Plasma and tissue levels of NOx. No differences in the
plasma levels of NOx (the Control 90 group versus the I/R
Figure 3 - Femoral artery concentration-response curves. (A) ACh (10-10 to 3.10-5 M); (B) A23187 (10-10 to 3.10-5 M); and (C) SNP (10-10 to
3.10-5 M) from the Control and Cilostazol groups. * Indicates the difference between the Control 120 and Cil groups (p,0.05).
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90/60 group and the Control 120 group versus the I/R
120/90 group) (Figure 5A) between the Control and I/R
groups were observed. Cilostazol administration prior to
and after ischemia increased plasma levels of NOx
compared to levels in the Control 120 group (Figure 5B).
In muscle tissues, 120 minutes of ischemia followed by 90
minutes of reperfusion increased the levels of NOx
(Figure 6A). Cilostazol treatment prior to and after
ischemia produced a stronger increased in NOx levels
compared to the levels found in the Control 120 and I/R
120/90 subgroups (Figure 6B).
DISCUSSION
The re-establishment of blood flow to ischemic tissues
or organs (i.e., reperfusion) is an essential step in many
surgical procedures. However, reperfusion often leads to I/
R injury, especially after a long period of ischemia (7). I/R
Figure 4 - Femoral artery concentration-response curves. (A, D) ACh (10-10 to 3.10-5 M); (B, E) A23187 (10-10 to 3.10-5 M); and (C, F) SNP
(10-10 to 3.10-5 M) from the Control, ischemia/reperfusion, and ischemia/reperfusion with cilostazol groups. * Indicates a difference
from the Control 120 group, and # indicates a difference from the I/R 120/90 group (p,0.05).
Table 1 - The EC50 values of sodium nitroprusside (SNP), acetylcholine (ACh), and the calcium ionophore (A23). The data
are expressed as means¡SEM.
Cont 90 I/R 90 Cont 120 I/R 120 Cil Cil/I/R I/Cil/R
ACh 6.28¡0.03 6.23¡0.04 6.31¡0.03 5.98¡0.03 6.14¡0.03 6.47¡0.03 5.99¡0.03
SNP 5.96¡0.01 5.95¡0.01 5.93¡0.02 5.96¡0.03 5.69¡0.08 5.88¡0.02 5.92¡0.02
A23 6.43¡0.01 6.40¡0.01 6.43¡0.01 6.52¡0.04 5.98¡0.14 6.20¡0.06 6.57¡0.03
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injury is characterized by an increase in free reactive oxygen
metabolites and cytokines, impaired NO production, the
activation of adhesion molecules and neutrophils, and the
promotion of lipid peroxidation with endothelial function
impairment (8). The present study confirmed the impor-
tance of I/R duration on endothelium dysfunction; namely,
an impairment of endothelium relaxation was observed in
the I/R 120/90 group but not in the I/R 90/60 group. This
result agrees with our previous experimental investigations
that demonstrated femoral artery endothelium dysfunction
in an I/R 120/90 group using an infrarenal clamp but
indicated no alteration in the endothelium-dependent
relaxation of the celiac trunk, renal, and superior mesenteric
arteries after I/R 60/30 of the supraceliac aorta (4,9).
The present study also demonstrated no significant
differences in the plasma levels of NOx between the groups.
An increase in the muscle levels of NOx was observed in the
I/R 120/90 group, but no significant differences between
the I/R and Cil groups were observed. The Cil/I/R group
exhibited greater relaxation compared to the I/R group. The
plasma levels of NOx were augmented in the Cil/I/R group.
The vascular reactivity results revealed that 120 minutes of
ischemia induced by infrarenal aortic cross-clamping fol-
lowed by 90 minutes of reperfusion reduced ACh- and
A23187-induced endothelium-dependent relaxation, but
these conditions did not affect the endothelium-independent
relaxation of rabbit femoral arteries. These data are consistent
with the results from two previous investigations that
described relaxation dysfunction in canine femoral arteries
after a 3 h/2 h hind limb I/R (4,10). Cilostazol administration
prior to ischemia partially prevented the impaired ischemia/
reperfusion-induced relaxation found in the current model.
This endothelial dysfunction indicated that the loss of NO-
mediated vasorelaxation is an initial manifestation of free
radical release during reperfusion. Cilostazol treatment
reduces the size of myocardial infarcts (3,11). Therefore, our
results showing the impairment of an endothelium-depen-
dent vasodilation suggest that the vascular dysfunction
found in our model is related to a reduced production of NO.
The reperfusion of ischemic tissue induces an acute
inflammatory response that results in necrosis and irrever-
sible vascular endothelial cell injury. However, the precise
role of the NO that is generated by iNOS and/or eNOS during
ischemia and reperfusion is controversial. The pharmacolo-
gical inhibition of eNOS NO synthesis has deleterious effects
on myocardial ischemia and reperfusion injury, but NO donor
treatment or the superinduction of iNOS attenuates reperfu-
sion-induced myocardial infarction and improves contractile
function (12-14). Also, iNOS inhibition abolishes the cardio-
protection resulting from ischemic preconditioning (15-18).
However, the enhanced release of NO may contribute to
ischemia and reperfusion injury, and NO inhibition may exert
cardioprotective effects (19-21).
Our data revealed that 120 minutes of ischemia followed
by 90 minutes of reperfusion increased NOx levels in
muscle tissues. However, this phenomenon was not
observed in plasma samples. Forty-five minutes of rat
Figure 5 - Concentration of plasma NOmetabolites in the Control
and ischemia/reperfusion (A) and Control, ischemia/reperfusion
and ischemia/reperfusion with cilostazol (B) groups. * Indicates a
difference from the Control 120 group (p,0.05).
Figure 6 - Concentration of muscle NO metabolites in the Control
and ischemia/reperfusion (A) and Control, ischemia/reperfusion
and ischemia/reperfusion with cilostazol (B) groups. * Indicates a
difference from the Control 120 group (p,0.05).
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kidney ischemia followed by 6 hours of reperfusion boosts
plasma levels of nitrite and nitrate, which are reduced by
an iNOS inhibitor (22). Wild-type mice exhibit increased
plasma NOx levels after myocardial I/R, but NOx species
are not detected in iNOS-deficient (iNOS2/2) mice (23). In
contrast, a decrease in NO below basal levels after hind limb
I/R (2.5 hours/2 hours) has been observed (24). These
results suggest that iNOS activation mediates the rise in
NOx after reperfusion.
Cilostazol administration prior to or after ischemia attenu-
ated vascular dysfunction and increased NOx levels in plasma
and muscle tissues. Several agonists have been found to
activate eNOS after an enhancement in intracellular free Ca2+
concentrations, but an alternative pathway for eNOS activa-
tion by the serine/threonine protein kinase, Akt, has also been
demonstrated, which should lead to an augmented release of
NO (11,25,26). Stimulation of the phosphatidylinositol-3-OH
kinase/Akt pathway improves serine phosphorylation and
induces eNOS activation and NO release.
Cilostazol activates Akt and eNOS to promote the
protective effect of statins and reduce infarct size. In addition,
cilostazol induces NO release in human aortic endothelial
cells through PKA-dependent eNOS phosphorylation (26).
Therefore, the cilostazol-induced production of NOx species
in the present work may be mediated by eNOS phosphoryla-
tion by Akt, the activation of protein kinase A (PKA), due to
increased intracellular cAMP or an unknown pathway.
Study limitation. The present study did not use a NOS
blocker to evaluate the effect of cilostazol on NO
bioavailability. However, a recent study investigated the
effect of systemic cilostazol administration on the ischemia-
induced neovascularization process in vivo and examined
the potential involvement of endothelial nitric oxide
synthase (eNOS) signaling in the cilostazol-regulated
neovascularization of ischemic muscles. The NOS inhibitor
l-NAME abrogated the involvement of eNOS signaling in
the neovascularization process (27).
In conclusion, 120 minutes of infrarenal aortic clamping
followed by 90 minutes of reperfusion culminates in
endothelium dysfunction, as suggested by the impaired
endothelium-dependent relaxation of the femoral artery.
Moreover, cilostazol administration prior to ischemia
exerted a protective effect on the endothelium-dependent
vascular reactivity under ischemia/reperfusion conditions.
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